{"id":728606,"date":"2023-02-03T08:48:06","date_gmt":"2023-02-03T13:48:06","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/"},"modified":"2023-02-03T08:48:06","modified_gmt":"2023-02-03T13:48:06","slug":"personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/","title":{"rendered":"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials"},"content":{"rendered":"

<\/p>\n

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials<\/b><\/p>\n

FREMONT, Calif.–(BUSINESS WIRE<\/a>)–
\nPersonalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform\u00aeas part of upcoming clinical studies evaluating mRNA-4157\/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The platform, which was also utilized in thevaccine candidate\u2019s Phase 2b clinical study, will be used to sequence genomic information from a patient\u2019s tumor sample to identify the unique genetic mutations that are most likely to generate a tailored antitumor response.\n<\/p>\n

\n\u201cFor years, we have been at the forefront of working with pharmaceutical partners, including Moderna, to apply our NeXT Platform to the sequencing of personalized cancer vaccines,\u201d said Chris Hall, President of Personalis. \u201cWe are thrilled to enter a new agreement with Moderna and support the next stage of clinical development for this program.\u201d\n<\/p>\n

\n\u201cWe are looking forward to continuing our partnership with Personalis on our personalized cancer vaccine program, with the goal of helping to bring truly individualized cancer treatment to patients,\u201d said Melanie Ivarsson, Moderna\u2019s Chief Development Officer.\n<\/p>\n

About Personalis<\/b><\/p>\n

\nPersonalis, Inc. is a leader in advanced cancer genomics, enabling the next generation of precision cancer therapies and diagnostics. The Personalis NeXT Platform<\/a>\u00ae is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers and clinicians with information on all of the approximately 20,000 human genes, together with the immune system, from a single sample. To enable cancer sequencing, Personalis’ Clinical Laboratory<\/a> was built with a focus on clinical accuracy, quality, big data, scale and efficiency. The laboratory is GxP-aligned as well as Clinical Laboratory Improvement Amendments of 1988-certified and College of American Pathologists-accredited. For more information, visit the Personalis website<\/a> and follow Personalis on LinkedIn<\/a> and Twitter<\/a>.\n<\/p>\n

Personalis Forward-Looking Statements<\/b><\/p>\n

\nAll statements in this press release that are not historical are \u201cforward-looking statements\u201d within the meaning of U.S. securities laws, including statements relating to attributes or advantages of the NeXT Platform, expected benefits of the company\u2019s collaboration with Moderna, Personalis\u2019 business opportunities, leadership, plans or expectations, or other future events. Such forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from any anticipated results or expectations expressed or implied by such statements. Factors that could materially affect actual results can be found in Personalis\u2019 filings with the U.S. Securities and Exchange Commission, including Personalis\u2019 most recent reports on Forms 8-K, 10-K and 10-Q, and include those listed under the caption \u201cRisk Factors.\u201d Personalis disclaims any obligation to update such forward-looking statements.\n<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230203005108\/en\/<\/a><\/span><\/p>\n

Personalis Contacts<\/b><\/p>\n

I<\/b>nvestors:
\n<\/b>
Caroline Corner
\n
investors@personalis.com
\n<\/a>
415-202-5678\n<\/p>\n

Media:
\n<\/b>
Jennifer Temple
\n
pr@personalis.com
\n<\/a>
650-752-1300\n<\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Biotechnology Technology Health Pharmaceutical Oncology Health Technology Medical Devices Research Genetics Science Clinical Trials<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials FREMONT, Calif.–(BUSINESS WIRE)– Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform\u00aeas part of upcoming clinical studies evaluating mRNA-4157\/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The platform, which was also utilized in thevaccine candidate\u2019s Phase 2b clinical study, will be used to sequence genomic information from a patient\u2019s tumor sample to identify the unique … <\/p>\n

Continue reading “Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-728606","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nPersonalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials FREMONT, Calif.–(BUSINESS WIRE)– Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform\u00aeas part of upcoming clinical studies evaluating mRNA-4157\/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The platform, which was also utilized in thevaccine candidate\u2019s Phase 2b clinical study, will be used to sequence genomic information from a patient\u2019s tumor sample to identify the unique … Continue reading "Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-03T13:48:06+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230203005108r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials\",\"datePublished\":\"2023-02-03T13:48:06+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/\"},\"wordCount\":549,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230203005108r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/\",\"name\":\"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230203005108r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-02-03T13:48:06+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230203005108r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230203005108r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/","og_locale":"en_US","og_type":"article","og_title":"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials - Market Newsdesk","og_description":"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials FREMONT, Calif.–(BUSINESS WIRE)– Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, and Moderna, Inc. (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the companies have signed a new agreement to continue using the Personalis NeXT Platform\u00aeas part of upcoming clinical studies evaluating mRNA-4157\/V940, an investigational personalized cancer vaccine, jointly developed by Moderna and Merck, known as MSD outside of the United States and Canada. The platform, which was also utilized in thevaccine candidate\u2019s Phase 2b clinical study, will be used to sequence genomic information from a patient\u2019s tumor sample to identify the unique … Continue reading \"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-03T13:48:06+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230203005108r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials","datePublished":"2023-02-03T13:48:06+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/"},"wordCount":549,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230203005108r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/","name":"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230203005108r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-02-03T13:48:06+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230203005108r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230203005108r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/personalis-and-moderna-sign-new-agreement-to-leverage-next-platform-in-personalized-mrna-cancer-vaccine-clinical-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Personalis and Moderna Sign New Agreement to Leverage NeXT Platform\u2122 in Personalized mRNA Cancer Vaccine Clinical Trials"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728606","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=728606"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/728606\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=728606"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=728606"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=728606"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}